CHORDS Intervention for Leukemia
(CHORDS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new support tool called CHORDS, a decision-making aid designed to assist people with myeloid cancers in deciding on a possible stem cell transplant. CHORDS uses digital stories from others who have faced similar choices and helps patients consider what matters most to them. The trial compares this new approach to the usual care patients receive. It seeks patients with myeloid cancers who are considering a stem cell transplant and can speak English. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could enhance decision-making support for future patients.
What prior data suggests that the CHORDS intervention is safe for patients with myeloid cancers considering alloHCT?
Research has shown that the CHORDS program offers a safe, non-invasive way for patients to decide about a type of stem cell transplant called alloHCT. It uses digital stories and activities to help patients identify what matters most to them. As an online educational tool, it presents no known physical risks or side effects.
The program does not involve drugs or medical procedures, so typical medical side effects are not a concern. Instead, it provides information and support to help patients understand their feelings and priorities, making it generally safe and easy to use.12345Why are researchers excited about this trial?
Researchers are excited about the CHORDS intervention for leukemia because it offers a unique approach to patient care by focusing on emotional and values-based support. Unlike traditional treatments that primarily focus on the medical aspects of care, CHORDS incorporates digital stories from previous patients and interactive exercises to help current patients clarify their emotions and priorities. This innovative approach aims to enhance the decision-making process and improve the overall patient experience during challenging times, potentially leading to better outcomes and patient satisfaction.
What evidence suggests that the CHORDS intervention is effective for patients considering alloHCT?
Research shows that allogeneic hematopoietic cell transplantation (alloHCT) can potentially cure certain blood cancers. Studies have found that some methods of this treatment have improved survival rates, with some patients living up to 83% longer over five years. However, deciding whether to undergo alloHCT can be difficult for patients. This trial tests the CHORDS program as an intervention to help patients understand their values and make informed decisions. The CHORDS program uses digital stories and exercises to help patients recognize their feelings and priorities, leading to better decision-making during tough times. Participants in the CHORDS arm will engage with these tools, while those in the usual care arm will receive standard care without the CHORDS intervention.36789
Are You a Good Fit for This Trial?
This trial is for English-speaking adults over 21 with myeloid cancers (like AML, MDS, myelofibrosis, CML, or MDS/MPN) who are considering allogeneic hematopoietic cell transplantation (alloHCT). They must be able to give informed consent.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants engage in the CHORDS intervention, which includes digital stories and values clarification exercises
Follow-up
Participants are monitored for feasibility and engagement in decision-making post-intervention
What Are the Treatments Tested in This Trial?
Interventions
- CHORDS
Trial Overview
The study tests a digital story and values clarification intervention called CHORDS against usual care. It aims to see if CHORDS helps patients with decision-making when they're considering alloHCT for leukemia treatment.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
The CHORDS intervention consists of 1) digital stories created by individuals who previously underwent consultation for alloHCT and 2) explicit values clarification exercises designed to help patients reflect on their emotions and clarify what matters to them, including a) an interactive workbook, and b) best-worst scaling (BWS).
Patients randomized to the usual care arm will receive standard of care. Patients (and their caregivers when available) randomized to usual care will not participate in CHORDS. Patients and caregivers will complete baseline (T1) and post-alloHCT office visit (T3, T4, T5) assessments.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Rochester
Lead Sponsor
Citations
Results of Children's Oncology Group Trial AALL0331 - PMC
The 6-year OS rate for > 5,000 children with SR ALL enrolled in AALL0331 exceeded 95%. The addition of IC to treatment for patients with SR-average disease did ...
2.
hematologyadvisor.com
hematologyadvisor.com/news/leukemia-haplo-cord-stem-cell-hct-effective-treatment-strategy/Haplo-Cord HCT May Be an Effective Treatment Strategy ...
Haplo-cord HCT offered improved 2-year OS (72.7% vs 61.0%) and DFS (67.0% vs 49.6%) compared with haplo HCT alone.
The hallmarks of hematopoietic stem cell transplantation ...
5-year EFS and OS rates were 77% and 83%, respectively, for HR patients with HSCT (85%) [112]. Intensification of induction, risk stratification ...
Improving outcomes of hematopoietic stem cell transplant ...
With a median follow-up of 902 days (52–2490), the probability of event free survival and overall survival (OS) was 65.9% and 69.4%. OS for lymphoid and myeloid ...
The Role of Allogeneic Hematopoietic Stem Cell ...
Allogeneic hematopoietic stem cell transplantation (HSCT) offers potentially curative treatment for many children with high-risk or relapsed acute leukemia ...
Outcomes of Allogeneic Hematopoietic Stem Cell ...
Haploidentical HSCT improved one-year survival (77.9% vs. 62.0% with chemotherapy) in elderly AML, with lower relapse (16.5% vs. 56.6%). Matched ...
Allogeneic Hematopoietic Cell Transplantation vs Standard ...
Nonrelapse mortality at 2 years after primary allogeneic HCT was 9% (95% CI, 5%-19%) and 2% (95% CI, 0%-11%) after consolidation chemotherapy (P ...
Decisions, decisions: factors that impact HCT outcomes in ...
They found that overall survival and relapse-free survival were highest in patients who received umbilical cord blood or matched donations ...
Survival Outcomes Based on Treatment Modality in Acute ...
Relative to patients who were treated with only chemotherapy, the patients who got chemotherapy and stem cell transplant (SCT) had 37% decreased risk of ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.